News – Page 1080 – Endpoints News

SIGN UP

Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new classes of antibiotics

8 years ago

FDA experts give a thumbs-up to Aerie Pharma’s glaucoma drug

8 years ago

That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it

8 years ago

OptiNose joins the biotech IPO fiesta, raises $120M in upsized offering

8 years ago

Ionis launches an early-stage tau drug study for Alzheimer’s, picking up $10M from Biogen

8 years ago

Biotech entrepreneur Saurabh Saha moves to translational research chief at Bristol-Myers; Ex-GSK pharma chief Hussain ...

8 years ago

Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work

8 years ago

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

8 years ago

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

FDA experts offer a unanimous endorsement for Spark’s pioneering AAV gene therapy for blindness

8 years ago

NIH allies with 11 top cancer biopharma players in $215M drive to explore biomarkers, speed R&D

8 years ago

Amgen’s Bradway elected PhRMA chair; Abingworth provides £13M A round to antiviral startup VirionHealth

8 years ago

Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

In a new setback, FDA kicks back AcelRx’s application for pain med — shares tank again

8 years ago

J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide

8 years ago

Positive PhIII can't salvage Merck's anacetrapib, now relegated to the scrap heap

8 years ago

Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug

8 years ago

Ardelyx steps up with a better round of PhIII data to compare with rivals at Ironwood, Synergy

8 years ago

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

8 years ago

The FDA's insider view on Aerie’s glaucoma drug: Yes on efficacy, but…

8 years ago

Ten big lobbying groups turn their guns on Allergan's controversial patent gambit

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Former FDA chief von Eschenbach steps up his advisory role at Malin

8 years ago

First page Previous page 1077 1078 107910801081 1082 1083 Next page Last page